Evolutec completes recruitment in Ph II rEV131 trial
UK biopharmaceutical group Evolutec says it has completed recruitment in a Phase II proof-of-concept trial of its lead development compound, rEV131. The drug is under assessment as an anti-inflammatory for use following cataract surgery.
The randomized, double-blind trial is being coordinated by Ophthalmic Research Associates, a Massachusetts, USA-based contract research organization, under the leadership of Mark Agelson. The program will compare the agent's anti-inflammatory properties with those of the steroid prednisolone, which is the most widely- prescribed medication for the prevention of post-operative ocular inflammation.
The firm said that it has increased the number of centers participating in the trial from 10 to 15, and added that it expects to publish results early in 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze